Is attribution quietly collapsing? |
We built modern marketing on a simple belief: If we can track it, we can prove it. Clicks. UTMs. Multi-touch dashboards. Clean source reporting. But in 2026, buyers don’t move in clean lines.
They research AI summaries, share links in Slack, take screenshots of posts, and forward decks internally. Then, they book a demo. And the CRM says: Direct traffic. |
You’re not imagining it. If you’re like most B2B buyers, you most likely start the purchase process with a shortlist of one or more preferred vendors (Forrester’s Buyer’s Journey Survey). Meanwhile, 41% of buyers already have a single vendor in mind. By the time they fill out your form, they’re already narrowing their choices. As a former pharmaceutical territory manager, this doesn’t surprise me. Physicians didn’t “discover” a drug in my office. They arrived with opinions shaped by journals, peers, and prior exposure. B2B buying is no different. The influence happens before the measurable moment. |
|
|
Influence Happens Before the CRM Knows It |
In pharma sales, I never assumed I was the first touchpoint.
By the time I walked into an office, the physician had already read clinical data, heard from colleagues, and evaluated reimbursement risk. If I treated the meeting like the beginning, I lost credibility. B2B sales teams are making the same mistake when they rely too heavily on attribution. Do these instead: 🧭 Separate lead source from deal readiness.
By the time a prospect fills out a form, the deal is rarely “starting.”
The typical B2B buying group now brings together around 10 members, based on 6sense’s report. That means influence isn’t happening in one conversation; it’s spreading across finance, operations, IT, procurement, and executive leadership.
In addition, buyers place four out of five vendors on their shortlist on day one of the journey, and 95% of the time, the final purchase comes from one of those initial four.
That should reframe how sales thinks about attribution. If your company wasn’t on that early shortlist, the opportunity may have been lost long before the demo request ever existed. In pharma, I learned quickly that by the time I sat down with a physician, competing therapies were already mentally shortlisted. My job wasn’t discovery; it was reinforcement and risk reduction. B2B sales works the same way. 📈 Stop fighting over credit and start measuring momentum. When marketing and sales argue over who “sourced” the deal, they’re asking the wrong question. The better questions are: |
- Did marketing help us make the shortlist?
- Did content reduce perceived risk across the buying group?
- Did the champion feel equipped to defend us internally?
|
If influence determined whether you were one of the four vendors considered on day one, that’s not lead generation. That’s positioning power. |
🔄 Build feedback loops, not just dashboards. If buying groups are large and shortlists form early, then post-deal feedback becomes critical. After every closed-won, capture: |
- When did you first hear about us?
- When did we make your shortlist?
- What made us defensible internally?
|
That tells you whether marketing is driving early inclusion, which matters more than last-touch credit. 🎯 Takeaway: Attribution used to prove origin. Now, it must prove shortlist inclusion and deal acceleration. |
|
|
Attribution models were built for a web where every meaningful interaction required a click. That web is fading, so measurement has to evolve.
Here are the three shifts I’m seeing and what I’d do about them (in pharma sales, influence seldom showed up cleanly in a dashboard, so I learned to look for directional proof). 🧩 Zero-click discovery is reshaping influence.
Prospects get answers in AI summaries and feeds without visiting your site. In my pharma territory, physicians absorbed journal takeaways and peer chatter long before they ever took my meeting; real impact despite no trackable trail. |
Pew found that when an AI summary appears in Google results, users are less likely to click through to other sites — a big reason “direct traffic” is swallowing your attribution.
If your traffic feels “missing,” it’s not in your head: Seer found AI Overviews correspond with a 61% organic CTR drop and 68% paid CTR drop on informational queries. What to do: |
-
Make content quotable + portable (clear claims, tight POV, simple visuals)
- Measure downstream: branded search lift, direct/demo trendlines, and the phrases prospects repeat on calls (not just clicks)
|
🔒 Private research is now the default.
Buyers share in Slack, DMs, screenshots, and internal decks. Your best asset may never generate a measurable session, and that doesn’t mean it failed. What to do: |
-
Build a late-stage “share pack” sales can forward internally:
- 1 slide: outcomes
- 1 slide: risk mitigation (security/implementation)
- 1 slide: proof (mini case + numbers)
- 1 slide: ROI assumptions
-
Ask sales to log what gets forwarded and whether it moved the deal forward
|
📊 Executives still want proof (but precision has limits).
Budget scrutiny hasn’t disappeared, and the answer here is a more credible proof stack. In pharma, I used prescribing trends + territory feedback + relationship depth: not perfect, but actionable. What to do: |
-
Add one self-reported question: “What prompted you to reach out now?”
- Capture win/loss notes: “What influenced the shortlist?”
- Track progression metrics: stage velocity, stakeholder expansion, time-to-meeting
|
🎯 Takeaway: The future of attribution is hybrid — quantitative signals for direction, plus qualitative confirmation for truth. |
|
|
Dashboard: “This campaign sourced 22% of the pipeline.”
Buyer: “We already had a shortlist.”
So, stop debating lead source and start capturing what attribution can’t see. Add two questions to your demo form and first call: “When did we make your shortlist?” and “What triggered outreach now?” Then, track shortlist entry and stage velocity, not just clicks. Influence earns shortlist inclusion, but momentum wins the deal. And attribution isn’t dead; it just needs backup. |
|
|
|
Bianca has spent the past four years helping businesses strengthen relationships and boost performance through strategic sales and customer engagement initiatives. Drawing on her experience in field sales and territory management, she transforms real-world expertise into actionable insights that drive growth and foster lasting client partnerships. |
|
|
Selling Signals is a TechnologyAdvice business © 2026 TechnologyAdvice, LLC. All rights reserved. TechnologyAdvice, 3343 Perimeter Hill Dr., Suite 215, Nashville, TN 37211, USA. |
|
|
|
